Kenya - İngilizce - Pharmacy and Poisons Board

harley's limited 63 westlands road - cefuroxime axetil - tablet - cefuroxime axetil 1500mg - ceftizoxime

İrlanda - İngilizce - HPRA (Health Products Regulatory Authority)

pharmacia ireland - clindamycin phosphate - concentrate for soln for inf - 150

İrlanda - İngilizce - HPRA (Health Products Regulatory Authority)

pharmacia ireland - clindamycin phosphate - concentrate for soln for inf - 150

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - clindamycin phosphate -

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - clindamycin phosphate -

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - clindamycin phosphate, quantity: 0 qs (equivalent: clindamycin, qty 150 mg/ml) - injection, solution - excipient ingredients: water for injections; benzyl alcohol; sodium hydroxide; disodium edetate; hydrochloric acid - indications as at 20 june 2005 : dalacin c phosphate is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. dalacin c phosphate is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci and staphylococci. its use should be reserved for penicillin - allergic patients or other patients for whom, in the judgement of the physician, a penicillin is inappropriate. anaerobes - serious respiratory tract infections such as empyema, anaerobic pneumonitis and lung abscess; serious skin and skin structure infections; septicaemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, non-gonococcal tubo-ovarian abscess, pelvic cellulitis and post-surgical vaginal cuff infection, all when given in conjunction with an antibiotic of appropriate gram

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - clindamycin phosphate, quantity: 0 qs (equivalent: clindamycin, qty 150 mg/ml) - injection, solution - excipient ingredients: disodium edetate; hydrochloric acid; water for injections; sodium hydroxide; benzyl alcohol - indications as at 20 june 2005 : dalacin c phosphate is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. dalacin c phosphate is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci and staphylococci. its use should be reserved for penicillin - allergic patients or other patients for whom, in the judgement of the physician, a penicillin is inappropriate. anaerobes - serious respiratory tract infections such as empyema, anaerobic pneumonitis and lung abscess; serious skin and skin structure infections; septicaemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract) and infections of the female pelvis and genital tract such as endometritis, non-gonococcal tubo-ovarian abscess, pelvic cellulitis and post-surgical vaginal cuff infection, all when given in conjunction with an antibiotic of appropriate g

Yeni Zelanda - İngilizce - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - clindamycin phosphate 178.22 mg/ml equivalent to clindamycin base 150 mg/ml;  ;  ;   - solution for injection - 600mg/4ml - active: clindamycin phosphate 178.22 mg/ml equivalent to clindamycin base 150 mg/ml       excipient: benzyl alcohol disodium edetate dihydrate hydrochloric acid sodium hydroxide water for injection - clindamycin phosphate has been shown to be effective in the treatment of the following infections when caused by susceptible anaerobic bacteria or susceptible strains of gram positive bacteria such as streptococci, staphylococci and pneumococci: 1. upper respiratory infections including tonsillitis, pharyngitis, sinusitis, otitis media and scarlet fever.

İrlanda - İngilizce - HPRA (Health Products Regulatory Authority)

imbat limited - clindamycin phosphate - solution for injection/infusion - 150 base mg/ml - lincosamides; clindamycin

İrlanda - İngilizce - HPRA (Health Products Regulatory Authority)

focus pharmaceuticals ltd - clindamycin - solution for injection/infusion - 150 milligram(s)/millilitre - lincosamides; clindamycin